NLRP3 and polycystic ovary syndrome: LSEE administration significantly reduced NF-κB and NLRP3 activation, leading to a subsequent decrease in pro-inflammatory cytokines IL-1β and IL-18, as well as a no significant activity on the anti-inflammatory cytokine IL-10, indicating its regulatory effect on inflammation in PCOS.